Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma | Zendy

Kenji Oyama | Zendy; Keita Kanki | Zendy; Hiroki Shimizu | Zendy; Yohei Kono | Zendy; Junya Azumi | Zendy; Kan Toriguchi | Zendy; Etsuro Hatano | Zendy; Goshi Shiota | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma

Author(s) -

Kenji Oyama,

Keita Kanki,

Hiroki Shimizu,

Yohei Kono,

Junya Azumi,

Kan Toriguchi,

Etsuro Hatano,

Goshi Shiota

Publication year - 2016

Publication title -

gastrointestinal tumors

Language(s) - English

Resource type - Journals

eISSN - 2296-3766

pISSN - 2296-3774

DOI - 10.1159/000448137

Subject(s) - hepatocellular carcinoma , melanoma , antigen , cancer research , medicine , oncology , immunology

Retinoids, vitamin A and its derivatives, have an antitumor effect on hepatocellular carcinoma (HCC). The function of retinoids is exerted by the complex of retinoic acid (RA) with the heterodimer of retinoid X receptor and the RA receptor. The preferentially expressed antigen of melanoma (PRAME) acts as a dominant repressor of RA signaling by binding to the complex. The significance of PRAME on the prognosis of HCC remains to be clarified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research